Chief Executive Officer
Peter Stein, CEO
Peter Stein is the Chairman and Chief Executive Officer of the Norgine Group. Norgine B.V., the primary subsidiary of the group, is a European specialist pharmaceutical company with operations throughout Europe, Australia and New Zealand. Peter also serves as the Chief Executive of Norgine Ventures, which provides financing solutions to innovative healthcare companies.
Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor.
Peter holds BA and MA degrees in Chemistry from Harvard University and an MBA from Stanford University.
In addition to his role at Norgine, Peter is a non-executive Director of Agendia N.V., a molecular diagnostics company based in Amsterdam.
Chief Operating Officer
Christopher Bath, COO
Christopher Bath is Norgine’s Chief Operating Officer.
Chris was appointed to the role of Chief Operating Officer in 2020, having previously served as Norgine’s Chief Financial Officer. He joined Norgine in 2014 from Shire plc, where he was Head of M&A.
His career in healthcare started in 2000, when he joined the Healthcare Investment Banking team at Rothschild, having qualified as a Chartered Accountant with Arthur Andersen. He spent the next 10 years at Rothschild working on and leading deals across the healthcare sector.
Chris originally trained as a scientist, reading Physics at Lady Margaret Hall, Oxford.
Ad Boon is the Chief Human Resources Officer at Norgine.
In his 27 year career to date, Ad has worked for Asea Brown Boveri, General Electric, and a combined 19-year tenure at NXP and Royal Philips, last as Senior Vice President Human Resources and Transformation. In the last 2 years after leaving Royal Philips, Ad has been focusing on supporting leaders and executive teams as an Executive Leadership Coach, as well as leading HR transformations.
After living and working in the US, Asia, the Middle East and Europe, he currently lives with his family in The Netherlands.
Alastair Benbow is the Chief Development and Medical Officer at Norgine.
Alastair is a physician with over 25 years of experience in the pharmaceutical industry.
Prior to joining Norgine in September 2016, Alastair worked for a number of companies including Fisons, Genentech, Synthelabo and spent 12 years working at GlaxoSmithKline (GSK). During his time at GSK, he held positions as UK Medical Director, Head of European Government Affairs, Head of Psychiatry Development, European Medical Director and SVP Global Safety and Pharmacovigilance and EU QPPV.
For three years, he held the role of Executive Director for the non-profit organisation, the European Brain Council and for three years he was Chief Medical Officer at Kinapse, where he led the Regulatory, Safety and Medical functions. He is a fellow of the Royal College of Physicians of Ireland and a Fellow of the Faculty of Pharmaceutical Medicine. In 2017 Alastair was appointed Chair of the Ethics and Practice Committee of the Faculty of Pharmaceutical Medicine.
Ewan Livesey is the Interim Chief Business Development Officer at Norgine.
Ewan has extensive Corporate and Business Development experience in the pharmaceutical industry. In his 25 year career to date, Ewan has completed numerous licensing and acquisition deals as well as advising on company strategy in relation to corporate development and portfolio management.
Prior to joining Norgine in 2021, Ewan has worked for a number of leading International companies including IVAX, Lupin, Glenmark, Apotex and most recently Zentiva. He is also a qualified lawyer.
Kenneth Scrimgeour is the Chief Commercial Officer at Norgine.
Ken has worked in a variety of sales, marketing and general management roles in the pharmaceutical industry in Europe and the US for the past twenty-eight years; either in local roles or within regional and global positions.
Ken has a BSc from Edinburgh University and he joined Norgine in 2004.
Lesley Roche is the Chief Financial Officer at Norgine.
Prior to joining Norgine in July 2020, Lesley was the Group Financial Controller at De La Rue plc, supporting the group in a number of business disposals as well as leading the team through its finance transformation.
Prior to joining De La Rue in 2016, Lesley worked for many years in the Life Science sector, spending 12 years at Amersham/GE Healthcare and 11 years at Shire. During her career she has had roles across all areas of finance and whilst at Shire Lesley was was responsible for the establishment of their global finance operations footprint and shared service centre strategy, as well as the integration of multiple acquisitions.
Marc Gorham is the IT Director at Norgine.
Marc joined Norgine in 2005 as Business Analyst to consolidate our ERP systems. Since then he has undertaken a variety of roles within the IT function, that he now leads, and has been instrumental in its evolution.
Prior to Norgine, Marc delivered technology initiatives as a consultant for PeopleSoft, JDEdwards and Catalyst Solutions across a variety of industry sectors.
His career started in healthcare during his 13 year tenure with Oxford Instruments.
Philippe Caroff is the Chief Manufacturing Officer at Norgine.
Philippe joined Norgine in 2013 as Director for External Network, looking after all outsourced manufacturing activities and since mid-2015 has also taken responsibilities for Supply Chain & Distribution activities.
Prior to this, Philippe has worked for a number of companies including Ipsen, Cap Gemini, Seagram and BP, in various positions in Manufacturing, Supply chain, Purchasing activities and also in Research & Development, with more than 15 years in the Pharmaceutical industry. Philippe graduated from Ecole des Mines de St Etienne in General Engineering.
Sheila Hopkins is the Chief Legal Officer at Norgine.
Prior to joining Norgine in 2006 Sheila worked for the law firm Latham & Watkins in London and New York and clerked for a Federal Court judge in the Second Circuit, New York.
Sheila holds a BA from Harvard College and a JD from the University of Pennsylvania Law School.